SEC Form 4 · accession 0001003642-17-000020
Impax Laboratories, LLC · IPXL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A Schlossberg
Officer — SVP and General Counsel
Period of report
Mar 2, 2017
Accepted (ET)
Mar 6, 2017 · 3:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001003642
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 2, 2017 | A | 23,272 | $0.00 | A | 105,179 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $9.35 | Mar 2, 2017 | A | 56,232 | A | — | Mar 2, 2027 | Common Stock | 56,232 | 56,232 | D |
Explanation of responses
- F1The option vests in four equal installments beginning on March 2, 2018, which is the first anniversary of the grant date.
Remarks
The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.